CGRP Antagonists for Treating Trigeminal Neuralgia
Provided for are methods of treating neuralgia, including trigeminal neuralgia with one or more CGRP receptor antagonists and/or pharmaceutical compositions thereof. Such methods are useful for treating, ameliorating, alleviating, providing for prophylaxis or prevention of, halting the progression of, and/or reducing the risk of neuralgia, including trigeminal neuralgia in a mammalian subject, such as a human. In particular, CGRP receptor antagonists such as those according to Formula I, Formula II, and/or Formula III as described herein are useful in methods of treating neuralgia, including trigeminal neuralgia in a subject in need thereof.
1 - 60 . (canceled)
61 . A method of treating, ameliorating, alleviating, providing for prophylaxis or prevention of, halting the progression of, and/or reducing the risk of trigeminal neuralgia, the method comprising administering to a subject in need thereof a CGRP receptor antagonist wherein the CGRP receptor antagonist is the compound (R)-N-(3-(7-methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)piperazin-1-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide, which has the following structure:
or a pharmaceutically acceptable salt thereof.
62 . The method of claim 61 , wherein the CGRP antagonist is administered in a unit dosage selected from the group consisting of about 10 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg, about 75 mg, about 80 mg, about 100 mg, about 120 mg, about 140 mg, about 160 mg, about 180 mg, or about 200 mg.
63 . The method of claim 61 , wherein the CGRP antagonist is administered in a dosage of 0.01-100 mg/kg body weight.
64 . The method of claim 61 , wherein the CGRP antagonist is administered in an amount corresponding to an area under curve (AUC) within about 80-125% of about 25, 50, 100, 150, 200, 250, 300, 400, 500, 600, 700, 800, 900, 1000, 1300, 1600, 1900, 2500, 3500, 5000, 7500, 10,000, 15,000, 20,000, 30,000, 50,000, or 100,000 hr*ng/mL.
65 . The method of claim 61 , wherein the CGRP antagonist is administered in an amount corresponding to a C max value within about 80-125% of about 1, 2, 3, 4, 5, 8, 10, 20, 35, 50, 80, 100, 150, 200, 250, 300, 400, 500, 600, 700, 800, 900, 1000, 1300, 1600, 1900, 2500, 3500, 5000, 7500, 10,000, 15,000, 20,000, 30,000, 50,000, and/or 100,000 ng/mL.
66 . The method of claim 65 , wherein the CGRP antagonist is administered in an amount corresponding to a C max /AUC ratio within about 80-125% of about 0.01, 0.03, 0.05, 0.08, 0.1, 0.13, 0.17, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.6, 0.7, 0.8, or 0.9.
67 . The method of a claim 61 , wherein the CGRP antagonist is administered at an interval of daily, twice daily, three times daily, four times daily, once every other day, once every two days, once every three days, once every four days, once every five days, once every six days, or once weekly.
68 . The method of a claim 61 , wherein the CGRP antagonist is administered by a route selected from oral, intrabuccal, intranasal, inhalation, parenteral, intravenous, topical, injectable and/or transdermal.
69 . The method of claim 61 , wherein the CGRP antagonist is administered in a unit dosage of 5 mg, 10 mg, or 20 mg.
70 . The method of claim 69 , wherein the CGRP antagonist is administered intranasally.
71 - 97 . (canceled)
98 . The method of claim 61 , the method comprising administering to a subject in need thereof a pharmaceutical composition comprising the CGRP receptor antagonist and one or more pharmaceutically acceptable carriers.
99 . The method of claim 98 , wherein the composition is formulated for oral administration.
100 . The method of claim 98 , wherein the composition is formulated for injectable administration.
101 . The method of claim 98 , wherein the composition is formulated for topical administration.
102 . The method of claim 61 , wherein the trigeminal neuralgia is trigeminal neuralgia type 1 (TN1), trigeminal neuralgia type 2 (TN2), or both TN1 and TN2.
103 . The method of claim 61 , wherein the treatment is characterized by an improvement in the Numeric Pain Rating Scale of at least 2 points compared to the patient baseline absent treatment.
104 - 106 . (canceled)